|Bid||0.84 x 0|
|Ask||0.85 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phivida Holdings Inc. ("Phivida" or the "Company") (CSE:VIDA) (PHVAF) announced today that it has closed its previously announced bought deal financing of 6,960,000 units (the “Units”) at a price of $1.15 per Unit (the “Offering Price”) for aggregate gross proceeds of approximately $8.0 million (the “Offering”). The Offering was conducted by a syndicate of underwriters, led by Canaccord Genuity Corp., acting as lead underwriter and sole bookrunner, and including Mackie Research Capital Corporation and Haywood Securities Inc. (collectively, the “Underwriters”). Each Unit consists of one common share (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”) of the Company.
OTCPK: PHVAF) is pleased to report the signing of a Letter of Intent (LOI) with Athletes for Care, Inc. (A4C). Terms of the LOI pertain to a prospective partnership in cannabinoid education and research with professional and amateur level athletics. The agreement comes equipped with an exclusivity to Phivida as the sole health-based cannabinoid infused beverage brand partner of A4C, contingent on a focus group trial sample from the inaugural Phivida beverage production run.
Clinical Study on Phivida's Nano-CBD™ at the University of Nottingham (UK) in Collaboration with Artelo Biosciences, Inc.